Physiopathology of ischemic stroke and its modulation using memantine:evidence from preclinical stroke

作     者：Hilda Martínez-Coria Isabel Arrieta-Cruz María-Esther Cruz Héctor E.López-Valdés Hilda Martínez-Coria;Isabel Arrieta-Cruz;María-Esther Cruz;Héctor E. López-Valdés

作者机构：División de InvestigaciónFacultad de MedicinaUniversidad Nacional Autónoma de México(UNAM)Ciudad de MéxicoMéxico Laboratorio Experimental de Enfermedades NeurodegenerativasFacultad de MedicinaUNAM/Instituto Nacional de Neurología y NeurocirugíaCiudad de MéxicoMéxico Departamento de Investigación BásicaInstituto Nacional de GeriatríaCiudad de MéxicoMéxico Unidad de Investigación en Biología de la ReproducciónLaboratorio de NeuroendocrinologíaFacultad de Estudios Superiores ZaragozaUNAMCiudad de MéxicoMéxico Unidad Periférica de NeurocienciaFacultad de MedicinaUNAM/Instituto Nacional de Neurología y NeurocirugíaCiudad de MéxicoMéxico 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2021年第16卷第3期

页      面：433-439页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100204[医学-神经病学] 10[医学] 

主　　题：focal ischemic stroke memantine neuroplasticity neuroprotection stroke therapy 

摘      要：Ischemic stroke is the most common type of cerebrovascular disease and is caused by an interruption of blood flow in the brain.In this disease,two different damage areas are identifying:the lesion core,in which cells quickly die;and the penumbra(surrounding the lesion core),in which cells are functionally weakened but may recover and restore their functions.The currently approved treatments for ischemic stroke are the recombinant tissue plasminogen activator and endovascular thrombectomy,but they have a short therapeutic window(4.5 and 6 hours after stroke onset,respectively)and a low percentage of stroke patients actually receive these treatments.Memantine is an approved drug for the treatment of Alzheimer s disease.Memantine is a noncompetitive,low affinity and use-dependent antagonist of N-methyl-D-aspartate glutamate receptor.Memantine has several advantages over developing a new drug to treat focal ischemic stroke,but the most important is that it has sufficient safe probes in preclinical models and humans,and if the preclinical studies provide more evidence about pharmacological actions in tissue protection and repair,this could help to increase the number of clinical trials.The present review summarizes the physiopathology of isquemic stroke and the pharmacological actions in neuroprotection and neuroplasticity of memantine in the post stroke stage of preclinical stroke models,to illustrate their potential to improve functional recovery in human patients.